Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
34 studies found for:    Von Hippel-Lindau Disease (VHL)
Show Display Options
Rank Status Study
21 Completed
Has Results
Phase II Study of Vandetanib in Individuals With Kidney Cancer
Conditions: Renal Cancer;   Von Hippel Lindau
Intervention: Drug: ZACTIMA (Vandetanib) (ZD6474)
22 Active, not recruiting Psychosocial Consequences of the Screening of Von Hippel Lindau Diseases for Patients Operated for a hémangioblastoma of Nervous Centrasl System
Condition: Hemangioblastoma (HB) of the Central Nervous System (CNS)
Intervention: Other: evaluation of anxiety with psychosocial scales
23 Terminated
Has Results
Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Biological: incomplete Freund's adjuvant;   Biological: von Hippel-Lindau peptide vaccine
24 Recruiting Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Von Hippel-Lindau Syndrome;   Hippel-Lindau Disease
Interventions: Drug: 68Gallium DOTATATE;   Procedure: Radio-guided surgery
25 Completed Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: 111Indium-bevacizumab;   Drug: 111Indium-cG250
26 Completed Metabolic Mapping to Measure Retinal Metabolism
Conditions: Macular Degeneration;   Diabetic Retinopathy;   Hippel-Landau Disease;   Mitochondria
Intervention: Procedure: Feasibility Study - Imaging System
27 Available Ruxolitinib for Chuvash Polycythemia
Condition: Erythrocytosis, Familial, 2
Intervention: Drug: Ruxolitinib
28 Terminated
Has Results
Vandetanib to Treat Advanced Kidney Cancer
Condition: Advanced Clear Cell Renal Carcinoma
Intervention: Drug: vandetanib
29 Unknown  pazopanib_NCRCC,Ph2 STUDY
Condition: Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma
Intervention: Drug: pazopanib
30 Recruiting National Eye Institute Biorepository for Retinal Diseases
Conditions: Age-Related Macular Degeneration;   Diabetic Retinopathy;   Von Hippel-Lindau Syndrome;   Retinal Disease;   Retinal Vein Occlusion
Intervention:
31 Recruiting Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders
Conditions: Kidney Cancer;   Urologic Malignant Disorders
Intervention:
32 Completed Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
Conditions: Coats' Disease;   Idiopathic Retinal Telangiectasia;   Retinal Angiomatous Proliferation;   Polypoidal Choroidal Vasculopathy;   Pseudoxanthoma Elasticum;   Pathological Myopia;   Multi-focal Choroiditis;   Rubeosis Iridis;   Von Hippel Lindau Disease;   BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Intervention: Drug: ranibizumab injection (0.5 mg)
33 Recruiting Diagnosis of Pheochromocytoma
Condition: Pheochromocytoma
Intervention:
34 Active, not recruiting A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Cabozantinib tablets;   Drug: Everolimus (Afinitor) tablets

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-34) Next Page   
Study has passed its completion date and status has not been verified in more than two years.